BPC-157

Body Protection Compound · C-tier (Dr. Alex Tatem) · Preclinical evidence

The most popular “healing” peptide. The animal data on tendons, ligaments and the gut is impressive. The human data is almost nonexistent.

Dr. Tatem’s take

C-tier: “We don’t really have any good clinical trials in humans.” On Diary of a CEO: “If you have an Achilles tendon injury and you’re a rat, BPC-157 is one of the best things.” Around the July 2026 FDA hearing, where he spoke, he told Fox News BPC-157 and TB-500 are “incredibly safe”.

In Dr. Tatem’s tier list

• Derived from a peptide found naturally in gastric juice and pitched as a way to speed the body’s own healing — “the holy grail” if it worked as claimed.
• In cell studies, fibroblasts (the wound-repair cells) organize more efficiently, but “most of that evidence is limited to either the benchtop or in animals.”
• Anecdotes swing from “this cured my spinal stenosis” to “sugar water,” muddied because people often stack it with TB-500 or GHK-Cu.
• What he hasn’t seen is serious side effects — which matters in a field where steroids and high-dose GH carry real harms. Gray-market contamination and heavy metals are the exception.
• Verdict: good reports + not-so-good reports + overall safety = “a solid C rating.”

History & background

BPC-157 (“Body Protection Compound”) is a 15-amino-acid fragment of a larger protein first described in human gastric juice by Predrag Sikirić and colleagues at the University of Zagreb, Croatia, in the early 1990s. Nearly all of the published research — well over a hundred animal papers on tendon, ligament, muscle, gut, and nerve injury — has come from that one group.

It was never developed as a commercial drug. Its popularity grew through bodybuilding forums and the research-chemical market in the 2010s. FDA placed it on its 503A “Category 2” (significant safety risk) list in 2023, removed it in April 2026 when the nomination was withdrawn, and in July 2026 an FDA advisory committee voted 8–6–1 to recommend it for compounding (ulcerative colitis). That vote is non-binding; rulemaking is still pending.

Benefits

• Faster tendon, ligament and muscle healing in rats.
• Protects and heals the gut lining in animal models.
• Promotes new blood-vessel growth to injured tissue.

Risks

• No systematic human safety data. FDA’s briefing noted 3 adverse-event reports.
• Theoretical: the same blood-vessel growth that helps healing could feed an existing tumor.
• Gray-market quality problems: wrong identity, impurities, contamination.

Dosing protocols (informational, labeled by evidence)

• Community (bro science): Typical community protocol — 250–500 mcg, SubQ (often near injury site), 1–2x daily, 4–6 wk (some 4–12 wk), repeatable
• Clinical trial / label: IV safety pilot (n=2) — 10 mg (day 1) then 20 mg in 250 mL saline, IV infusion, 2 infusions, Single pilot
• Clinical trial / label: Intravesical pilot (interstitial cystitis) — 10 mg total, Injection into bladder wall, Single treatment, Single

Status: Not approved. FDA advisers voted 8–6–1 in July 2026 to allow compounding (for ulcerative colitis). The vote isn’t binding and rulemaking is pending, so it can’t legally be compounded yet.

Grade and commentary: Dr. Alex Tatem. Watch: BPC-157 & TB-500: The Truth About the Wolverine Stack, The Truth About Popular Peptides (What Works, What’s Overhyped) | Peptide Tier List pt.1, FDA Just Changed the Future of Peptides, Peptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex Tatem. Subscribe: @DrAlexTatem.